Story
Travere Therapeutics Taps Amicus Veteran as New CEO; Shares Dip on Transition News
Travere Therapeutics (NASDAQ: TVTX) announced a planned leadership transition on Monday, causing its shares to fall in after-hours trading. The biopharmaceutical company named Bradley L. Campbell, former CEO of Amicus Therapeutics, as its next president and chief executive officer, succeeding Eric Dube, Ph.D., who is stepping down for personal health and family reasons.
The Leadership Handover
The company confirmed the transition will be effective December 1, 2026. Dr. Dube will continue in his role as president and CEO until that date to ensure a smooth handover. Following the transition, he will remain with the company as an executive advisor through February 15, 2027.
Gary Lyons, chairman of Travere's Board of Directors, stated that the board conducted a comprehensive search and selected Campbell for his scientific, commercial, and operational expertise. The board highlighted his track record in scaling rare disease therapies and advancing clinical pipelines as key qualifications for leading Travere's next phase.
Incoming and Outgoing CEO Profiles
AdBradley L. Campbell brings over 25 years of experience in the biopharmaceutical industry. He most recently served as president and CEO of Amicus Therapeutics, where he spent nearly 20 years in roles of increasing responsibility. During his tenure, Amicus grew from a single-product company into a global rare disease organization. His prior experience includes roles at Genzyme and Bristol-Myers Squibb.
Dr. Dube has served as Travere's CEO since January 2019. During his leadership, the company secured regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis (FSGS) and expanded its pipeline.
Market Reaction
Following the announcement, shares of Travere Therapeutics fell by as much as 2.3% in after-hours trading on Monday. Leadership changes, even when planned, can create short-term uncertainty among investors, often resulting in modest stock price fluctuations as the market assesses the new executive's potential impact on company strategy and performance.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.